维持性血液透析患者皮肤瘙痒症发生情况及其危险因素分析
Analysis of the Occurrence and Risk Factors of Skin Pruritus in Patients with Maintenance Hemodialysis
摘要: 目的:分析维持性血液透析(MHD)患者皮肤瘙痒症发生情况及其危险因素。方法:研究对象选自我院于2019年8月~2021年10月收治的197例MHD患者,并对其临床资料进行回顾性分析,将出现皮肤瘙痒症的患者纳入A组,其余纳入B组。统计197例MHD患者发生皮肤瘙痒症的情况,比较两组临床资料,危险因素予以多因素Logistic回归分析法分析。结果:MHD患者皮肤瘙痒症发生率为34.52%。透析时间长(OR = 1.430)、皮肤干燥(OR = 4.850)、血磷(OR = 3.751)、血镁水平高(OR = 5.186)、匹兹堡睡眠质量指数(PSQI)评分高(OR = 1.449)、严重抑郁(OR = 2.132)是MHD患者发生皮肤瘙痒症的独立危险因素(P < 0.05)。结论:MHD患者出现皮肤瘙痒症的发生率较高,且其危险因素有透析时间长、皮肤干燥、血磷、血镁水平高、PSQI评分高、严重抑郁等。
Abstract: Objective: To analyze the occurrence and risk factors of skin pruritus in patients with maintenance hemodialysis (MHD). Method: The research subjects were selected from 197 MHD patients admitted to our hospital from August 2019 to October 2021, and their clinical data were retrospectively analyzed. Patients with pruritus were included in group A, and the rest were included in group B. Statistical analysis was conducted on the occurrence of pruritus in 197 patients with MHD, and clinical data were compared between the two groups. Multivariate Logistic regression analysis was used to analyze the risk factors. Result: The incidence of pruritus in MHD patients is 34.52%. Long dialysis time (OR = 1.430), dry skin (OR = 4.850), blood phosphorus (OR = 3.751), high blood magnesium levels (OR = 5.186), high Pittsburgh Sleep Quality Index (PSQI) score (OR = 1.449), and severe depression (OR = 2.132) were independent risk factors for skin itching in MHD patients (P < 0.05). Conclusion: The incidence of skin pruritus in MHD patients is high, and its risk factors include long time of dialysis, dry skin, high level of blood phosphorus and blood magnesium, high score of PSQI, and severe depression.
文章引用:古兰木拜尔·安尼瓦尔. 维持性血液透析患者皮肤瘙痒症发生情况及其危险因素分析[J]. 临床医学进展, 2025, 15(12): 2588-2593. https://doi.org/10.12677/acm.2025.15123692

1. 引言

终末期肾衰竭患者需进行维持性血液透析(MHD)治疗,但在治疗过程中,患者可能并发皮肤瘙痒症,导致患者出现全身性或局部瘙痒,进而使患者不自主地抓挠皮肤,影响透析过程,且患者还因持续性的瘙痒而无法正常睡眠,导致其睡眠质量下降,出现焦虑、抑郁等的情绪,严重影响MHD患者生活质量[1] [2]。当前,临床对MHD患者出现皮肤瘙痒症的影响因素仍无一致结论,导致其防治难度加大[3]。基于此,本研究通过分析我院收治的197例MHD患者皮肤瘙痒症的发生情况及危险因素,旨在为MHD患者皮肤瘙痒症的防治提供依据,结果报道如下。

2. 资料与方法

2.1. 临床资料

研究对象选自我院于2019年8月~2021年10月收治的197例MHD患者,并对其临床资料进行回顾性分析,将出现皮肤瘙痒症的患者纳入A组,其余纳入B组。A组、B组的具体临床资料见表1。纳入标准:年龄 > 20周岁,透析时长 > 3个月,皮肤瘙痒症的诊断标准符合《皮肤瘙痒防治》[4]中相关诊断标准者;有完整的临床资料者等。排除标准:皮肤感染、恶性肿瘤、药物性皮疹、特发性皮炎、湿疹、过敏性荨麻疹导致的皮肤瘙痒者;近期使用细胞毒性药物、激素类药物者;近期出现严重创伤、肝病、手术、肿瘤及自身免疫疾病患者。

2.2. 发生情况及临床资料收集

分析197例MHD患者发生皮肤瘙痒症的情况,并收集A组、B组的年龄、性别、超滤量、透析时间、甲状旁腺激素、皮肤干燥、血钙、血磷、血镁、匹兹堡睡眠质量指数[5] (PSQI)评分、焦虑程度、抑郁程度等资料。抽取MHD患者外周血4 mL,以生化分析仪(浙江普施康生物科技有限公司,型号:MS100)测定全血甲状旁腺激素、血钙、血磷、血镁水平。PSQI评分总分为0~21分,PSQI评分与患者睡眠质量成反比。焦虑程度、抑郁程度以医院焦虑抑郁量表[6]测定,包含焦虑、抑郁2个亚量表,总分均为21分,其中焦虑亚量表总分 < 10分、抑郁亚量表总分 < 7分分别表示焦虑程度、抑郁程度轻微。

2.3. 统计学方法

通过SPSS 21.0软件数据进行处理分析。计量资料:( χ ¯ ±s ),t检验。计数资料:[n(%)],χ2检验。危险因素予以多因素Logistic回归分析法分析。P < 0.05为差异有统计学意义。

3. 结果

3.1. 发生情况及临床资料分析

197例MHD患者发生皮肤瘙痒症68例,发生率为34.52%。A组透析时间长于B组(P < 0.05),全血甲状旁腺激素、血磷、血镁水平、PSQI评分及皮肤干燥、严重抑郁患者占比均高于B组(P < 0.05);而A组、B组年龄、性别、超滤量、血钙水平、焦虑程度比较,差异无统计学意义(P > 0.05)。见表1

Table 1. Analysis of clinical data between the two groups

1. 两组临床资料分析

因素

A组(68例)

B组(129例)

t/χ2

P

年龄( χ ¯ ±s ,岁)

56.38 ± 10.27

55.85 ± 12.75

1.494

0.137

性别[n(%)]

-

-

0.009

0.924

30 (44.12)

56 (43.41)

-

-

38 (55.88)

73 (56.59)

-

-

超滤量( χ ¯ ±s , mL)

731.75 ± 294.27

730.86 ± 297.27

1.043

0.298

透析时间( χ ¯ ±s ,年)

9.83 ± 1.27

8.26 ± 1.19

8.601

<0.001

全血甲状旁腺激素( χ ¯ ±s , pg/mL)

437.83 ± 74.74

361.47 ± 58.86

65.886

<0.001

皮肤干燥[n(%)]

-

-

5.997

0.014

36 (52.94)

45 (34.88)

-

-

32 (47.06)

84 (65.12)

-

-

血钙( χ ¯ ±s , mmol/L)

2.31 ± 0.16

2.25 ± 0.28

1.631

0.105

血磷( χ ¯ ±s , mmol/L)

1.67 ± 0.23

1.21 ± 0.17

15.926

<0.001

血镁( χ ¯ ±s , mmol/L)

1.32 ± 0.14

0.69 ± 0.06

44.075

<0.001

PSQI评分( χ ¯ ±s ,分)

12.15 ± 0.85

6.35 ± 0.47

61.186

<0.001

焦虑程度[n(%)]

-

-

2.960

0.085

严重

3 (4.41)

1 (0.78)

-

-

轻微

65 (95.59)

128 (99.22)

-

-

抑郁程度[n(%)]

-

-

60.474

<0.001

严重

29 (42.65)

1 (0.78)

-

-

轻微

39 (57.35)

128 (99.22)

-

-

3.2. MHD患者发生皮肤瘙痒症的危险因素分析

透析时间长(OR = 1.430)、皮肤干燥(OR = 4.850)、血磷(OR = 3.751)、血镁水平高(OR = 5.186)、匹兹堡睡眠质量指数(PSQI)评分高(OR = 1.449)、严重抑郁(OR = 2.132)是MHD患者发生皮肤瘙痒症的独立危险因素(P < 0.05)。见表2

Table 2. Analysis of risk factors for skin pruritus in MHD patients

2. MHD患者发生皮肤瘙痒症的危险因素分析

变量

β

SE

Wald/χ2

P

OR

95%CI

透析时间长

0.358

0.025

205.062

<0.001

1.430

1.362~1.502

甲状旁腺激素水平高

0.136

0.084

2.621

0.105

1.146

0.972~1.351

皮肤干燥

1.579

0.397

15.819

<0.001

4.850

2.228~10.560

血磷水平高

1.322

0.354

13.946

<0.001

3.751

1.874~7.507

血镁水平高

1.646

0.546

9.088

0.003

5.186

1.779~15.122

PSQI评分高

0.371

0.054

47.202

<0.001

1.449

1.304~1.611

严重抑郁

0.757

0.153

24.480

<0.001

2.132

1.580~2.877

3.3. 典型病例

患者张某,年龄42岁,因出现高磷血症导致并发皮肤瘙痒症,并导致患者出现疤痕。

4. 讨论

MHD患者在长期的治疗过程中,可能出现皮肤瘙痒症、高血压、肾性贫血、凝血功能异常、脑出血等并发症,其中,皮肤瘙痒症会导致MHD患者皮肤出现阵发性瘙痒,且夜间症状更明显,使得患者夜间睡眠质量下降,身体出现抓痕、血痂及色素,患者的睡眠及皮肤健康会受到严重影响。

本研究结果表明,MHD患者皮肤瘙痒症发生率为34.52%,说明MHD患者皮肤瘙痒症高发。本研究结果还显示,A组透析时间长于B组,甲状旁腺激素、血磷、血镁水平、PSQI评分、皮肤干燥、严重抑郁患者占比均高于B组,提示MHD患者出现皮肤瘙痒症可能与患者透析时间、甲状旁腺激素、血磷、血镁水平、PSQI评分、皮肤干燥、抑郁程度有关,与既往研究[7]结果一致。多因素Logistic回归分析结果显示,透析时间长(OR = 1.430)、皮肤干燥(OR = 4.850)、血磷(OR = 3.751)、血镁水平高(OR = 5.186)、匹兹堡睡眠质量指数(PSQI)评分高(OR = 1.449)、严重抑郁(OR = 2.132)是MHD患者发生皮肤瘙痒症的独立危险因素。分析其机制可能为,透析时间长的MHD患者,体内的炎性因子因透析过程中难以滤过,导致其体内炎性因子水平持续升高,导致皮肤柱状细胞释放组织胺,故而透析时间长与皮肤瘙痒症具有一定关联,但其对皮肤瘙痒症发生、发展的影响机制仍需进一步探讨[8]。因此,临床需给予透析时间长的MHD患者抗组胺药物治疗,以避免控制患者表皮组胺水平升高。皮肤干燥的MHD患者会出现皮脂腺萎缩、汗腺、外分泌功能减退等情况,进而可能诱发患者出现皮肤瘙痒症,与皮肤瘙痒密切相关[9] [10]。因此,临床需告知患者保湿工作,如根据情况使用含尿素或神经酰胺的润肤乳,避免因皮肤干燥引发皮肤瘙痒症。血磷、血镁水平高的MHD患者,可能会出现高磷血症,使得磷、镁沉积于皮肤表面,加大患者出现皮肤瘙痒症的风险[11] [12]。临床上可针对血磷、血镁水平高的MHD患者补给生理盐水,以控制其血磷、血镁水平。PSQI评分高的MHD患者存在睡眠障碍的问题,而睡眠不足会进一步导致患者体内组胺释放增多,进而使得皮肤出现皮肤瘙痒的症状,加大患者并发皮肤瘙痒症的风险[13] [14]。因此,临床上可建议睡眠不足的MHD患者多食用富含维生素B的食物,同时,需给予有严重睡眠问题的MHD患者安眠药治疗,或通过运动疗法、环境调整等方式,同时督促患者养成良好的睡眠习惯,以改善患者睡眠质量,降低其发生皮肤瘙痒症的风险。此外,有研究[15] [16]表明,严重抑郁的MHD患者体内组胺释放量高于情绪正常的MHD患者,而组胺会通过与皮肤表面靶细胞结合产生瘙痒感,故严重抑郁的MHD患者发生皮肤瘙痒症的风险也相对较高。故临床需给予严重抑郁的MHD患者心理干预,改善患者心理状态,进而减少出现皮肤瘙痒症。

综上,MHD患者出现皮肤瘙痒症的发生率较高,且其危险因素有透析时间长、皮肤干燥、血磷、血镁水平高、PSQI评分高、严重抑郁等,临床可根据以上危险因素对MHD患者进行防治,以避免其出现皮肤瘙痒症。

研究局限性,本研究选取的患者有一定的地域性,可能受当地的气候、饮食等因素的影响,且纳入样本量较少,可能存在选择偏倚,因此,临床可进一步扩大选例范围进行进一步分析。

声 明

该病例报道已获得病人的知情同意。

参考文献

[1] 王英, 于明安, 杨秀梅, 等. 尿毒症患者继发性甲状旁腺增生结节微波消融治疗的临床观察[J]. 新疆医学, 2017, 47(5): 485-487, 491.
[2] 古兰木拜尔∙安尼瓦尔. 血液透析联合血液灌流治疗慢性肾衰竭并骨代谢异常的疗效观察[J]. 新疆医学, 2021, 51(1): 49-51.
[3] 王智斌, 赵玢. 炉甘石洗液外用联合加巴喷丁治疗老年皮肤瘙痒症的疗效观察[J]. 贵州医药, 2020, 44(10): 1604-1605.
[4] 姚春海, 宋志军. 皮肤瘙痒防治[M]. 北京: 金盾出版社, 2002: 353-355.
[5] 王线妮, 袁琰琴, 任婷婷, 等. 重症肌无力患者睡眠质量及影响因素分析[J]. 中华全科医学, 2019, 17(11): 1812-1814, 1832.
[6] 李宁, 徐妙, 张维, 等. 叙事医学模式对青年乳腺癌化疗患者心理状况及生存质量的影响[J]. 贵州医科大学学报, 2018, 43(6): 682-685.
[7] Abdelsalam, M., Tawfik, M., Reda, E.M., Eldeeb, A.A., Abdelwahab, A., Zaki, M.E., et al. (2019) Insulin Resistance and Hepatitis C Virus-Associated Subclinical Inflammation Are Hidden Causes of Pruritus in Egyptian Hemodialysis Patients: A Multicenter Prospective Observational Study. Nephron, 143, 120-127. [Google Scholar] [CrossRef] [PubMed]
[8] Gu, Y.H., Yang, X.H., Pan, L.H., Zhan, X.L., Guo, L.L. and Jin, H.M. (2019) Additional Hemoperfusion Is Associated with Improved Overall Survival and Self-Reported Sleep Disturbance in Patients on Hemodialysis. The International Journal of Artificial Organs, 42, 347-353. [Google Scholar] [CrossRef] [PubMed]
[9] Khorsand, A., Salari, R., Noras, M.R., Saki, A., Jamali, J., Sharifipour, F., et al. (2019) The Effect of Massage and Topical Violet Oil on the Severity of Pruritus and Dry Skin in Hemodialysis Patients: A Randomized Controlled Trial. Complementary Therapies in Medicine, 45, 248-253. [Google Scholar] [CrossRef] [PubMed]
[10] Forner, C., Zeidler, C., Stein, P., Stössel, E., Wefelmeier, L., Peukert, N., et al. (2019) Woad Extract Containing Cream Improves Significantly Dry, Irritated, and Pruritic Skin. Dermatologic Therapy, 32, e12939. [Google Scholar] [CrossRef] [PubMed]
[11] Cheng, T., Tarng, D., Liao, Y. and Lin, P. (2016) Effects of Systematic Nursing Instruction on a Low‐Phosphorus Diet, Serum Phosphorus Level and Pruritus of Patients on Haemodialysis. Journal of Clinical Nursing, 26, 485-494. [Google Scholar] [CrossRef] [PubMed]
[12] Ketteler, M., Wiecek, A., Rosenkranz, A.R., Pasch, A., Rekowski, J., Hellmann, B., et al. (2021) Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis—A Randomized Clinical Trial. Kidney International Reports, 6, 594-604. [Google Scholar] [CrossRef] [PubMed]
[13] Díez García, A. and Garzón García, M. (2017) Regulación de las fases del ciclo vigilia-sueño por la histamina [Regulation of the Phases of the Sleep-Wakefulness Cycle with Histamine]. Revista de Neurología, 64, 267-277. [Google Scholar] [CrossRef
[14] Yu, X., Franks, N.P. and Wisden, W. (2018) Sleep and Sedative States Induced by Targeting the Histamine and Noradrenergic Systems. Frontiers in Neural Circuits, 12, Article 4. [Google Scholar] [CrossRef] [PubMed]
[15] Malm, L. (2019) Re‐Sensitization of Desensitized Histamine H1 Receptors in the Human Skin Takes More than 18 Hours. Skin Research and Technology, 26, 61-66. [Google Scholar] [CrossRef] [PubMed]
[16] Yoshida, H., Aoki, M., Komiya, A., Endo, Y., Kawabata, K., Nakamura, T., et al. (2020) HYBID (Alias KIAA1199/CEMIP) and Hyaluronan Synthase Coordinately Regulate Hyaluronan Metabolism in Histamine-Stimulated Skin Fibroblasts. Journal of Biological Chemistry, 295, 2483-2494. [Google Scholar] [CrossRef] [PubMed]